

Francesco Pignatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2058003/publications.pdf>

Version: 2024-02-01

5
papers

47
citations

2258059

3
h-index

2053705

5
g-index

5
all docs

5
docs citations

5
times ranked

32
citing authors

#	ARTICLE	IF	CITATIONS
1	The value of anticancer drugs – a regulatory view. Nature Reviews Clinical Oncology, 2022, 19, 207-215.	27.6	14
2	The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease. HemaSphere, 2021, 5, e604.	2.7	3
3	The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia. HemaSphere, 2021, 5, e616.	2.7	2
4	The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. HemaSphere, 2021, 5, e666.	2.7	5
5	The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation. Clinical Cancer Research, 2011, 17, 5220-5225.	7.0	23